Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGKV3D-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3D-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3D-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3D-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3D-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3D-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV5-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV5-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV5-2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV4-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV4-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV4-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3D-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3D-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV3-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV3-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV2D-28 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV2D-28 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV2D-28 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV2D-40 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV2D-40 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV2D-40 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →